Σοφία – Παρασκεύη Τραχανά ΜΑΙΕΥΤΗΡΑΣ - ΓΥΝΑΙΚΟΛΟΓΟΣ MD, MSc, PhD, Fertility Specialist

Θέμα: «Μελέτη των σχετιζόμενων με την αγγειογένεση παραγόντων και πρωτεϊνών σε ασκητικό υγρό ασθενών με καρκίνο των ωοθηκών.»

Θεραπευτική Κλινική Ιατρικής Σχολής ΕΚΠΑ (2010 – 2016)

• Ιατρικός Σύλλογος Αθηνών

• GMC, General Medical Council UK

• ESHRE, European Society of Human Reproduction and Embryology

• Ελληνική Εταιρεία Διατήρησης Αναπαραγωγής

• 7^ος/2020 – ongoing : Συνεργάτης Μονάδας Υποβοηθούμενης Αναπαραγωγής “ΑΚΕΣΩ – EmbryoArt”.

• 7^ος/ 2020 – ongoing : Πανεπιστημιακός Υπότροφος Γ’ Μαιευτικής-Γυναικολογικής Κλινικής ΠΓΝΑ «ΑΤΤΙΚΟ» – Μονάδα Υποβοηθούμενης Αναπαραγωγής

• 2018-2020: Clinical Fellow in Reproductive Medicine – St. Bart’s Fertility Clinic, London, UK.

• 2017-2018: Επιστημονικός συνεργάτης Γ.Ν.Α “Αλεξάνδρα” – Μονάδα Υποβοηθούμενης Αναπαραγωγής

• 2015-2017: Ειδικότητα Μαιευτικής – Γυναικολογίας Γ.Ν.Α “Αλεξάνδρα”.

• 2013-2015: Ειδικότητα Μαιευτικής – Γυναικολογίας ΕΑΝΠ “Μεταξά”

• 2010-2011: Ειδικότητα Γενικής Χειρουργικής Γ.Ν.Α “Πατησίων”.

• 2009-2013: Θεραπευτική κλινική Ιατρικής Σχολής EΚΠΑ. Συμμετοχή (Sub-Investigator) σε ερευνητικά πρωτόκολλα Ογκολογίας.

• 2007-2008: Ιατρός σχολικών αγώνων.

• Υποβοηθούμενη Αναπαραγωγή

• Γυναικολογική Ενδοκρινολογία

• Διατήρηση Γονιμότητας

• Μαιευτική-Γυναικολογία

• Ιδιαίτερο ενδιαφέρον και εξειδίκευση στη διατήρηση γονιμότητας γυναικών με καρκίνο.

2012-2013: 2 έτη χρηματοδότησης της διδακτορικής διατριβής από την Ένωση Ογκολόγων – Παθολόγων Ελλάδος (ΕΟΠΕ)

• Contemporary Oncology

• Archives of Gynecology and Obstetrics (Arch Gynecol Obstet)

• Journal of Obstetrics and Gynaecology Research (J Obstet Gynaecol Res)

• Reproductive Biology and Endocrinology (Reprod Biol Endocrinol)

• British Journal of Cancer (BJC)

• Book Chapter: Aromatase Inhibitors in IVF protocols.

Sofia-Paraskevi Trachana, J. Pundir (St Bart’s Fertility Unit, London, UK)

Textbook of ART under Indian Fertility Society (2019-2020).

• S-P Trachana, E. Pilalis, D. Mavrogianni, et al. “Study of a protein based angiogenic profile in endometrial tissue of women undergoing assisted reproductive techniques.” Clinical Practice Therapy Clin. Pract. 963 (2018) 15(7), 963-976 (MSc Dissertation).

• S-P. Trachana, M. Fanaki, N. Thomakos. “Pregnancy Outcomes after Radical Trachelectomy. Is it Only a Matter of surgery? – Editorial”. British Journal of Research, Jan 2018, Vol.4 No.5:36

• S-P Trachana, N, Thomakos, D. Haidopoulos, et al. “Does conservative treatment reflects the best choice in women with adenocarcinoma in situ of the uterine cervix? A single-institutional study.” Gynecologic Oncology, June 2017, Volume 145:p186-187

• Besharat , E. Domali , S-P. Trachana, et al. “Ectopic pregnancies and treatment: surgery is not the only choice”. Ultrasound in Obstetrics & Gynecology, August 2017; 50(S1):229-229.

• Domali, A. Besharat, S-P. Trachana, et al. “Risk of borderline malignancy and ultrasonic assessment”. Ultrasound in Obstetrics & Gynecology, September 2017;50(S1):379-379

• Domali, SP. Trachana, D. Loutradis, et al. “Ectopic pregnancy: combination of 2D real time and 3D ultrasonography ensures the diagnosis”. Ultrasound in Obstetrics & Gynecology, Sep 2016; S1:372-373.

• Thomakos, S-P. Trachana, M. Liontos, et al. “Why Radical Trachelectomy and not Radical Hysterectomy for the treatment of early stage cervical cancer? HJOG. Sep 2016; 15(3)

• Trachana SP, Pilalis E, Gavalas NG, et al. “The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.” PLoS One. 2016 Jun 3;11(6):e0156403 (PhD thesis).

• Thomakos N, Trachana SP, Davidovic-Grigoraki M, et al. “Less radical surgery for early stage cervical cancer. To what extent do we justify for? – our belief” Taiwanese Journal of Obstetrics and Gynecology. 2016;4:495-498.

• Thomakos, I. Koutroumpa, S.P. Trachana, et al “Significance of omentectomy during surgical staging for uterine serous carcinoma”. Gynecologic Oncology, April 2015; 137.

• Thomakos N, Trachana SP, Koutroumpa I, et al. “Molecular aspects and clinical methods for preserving ovarian reserves in women receiving cancer chemotherapy treatment.” Clin Exp Obstet Gynecol. 2015;42(4):416-25.

• Koutroumpa, N. Thomakos, M. Sotiropoulou, P. Trachana, et al. “Clinicopathological prognostic factors for recurrence in adult granulosa cell tumor of the ovary”. Gynecologic Oncology, June 2014; 133(9):84. 

• Thomakos, M. Sotiropoulou, D. Zacharakis, I. Koutroumpa, E. Valla, S.P. Trachana, et al. “A new suggested pattern-based clinical classification system for endocervical adenocarcinoma”. Gynecologic Oncology, June 2014; 133:62-63.

• Gavalas NG, Trachana SP, Dimopoulos MA, Bamias A. “Angio-Inhibitors in Ovarian Cancer” Cancer Sci Ther 2014; 6:11. doi:10.4172/1948-5956.1000309.

• P Trachana, NG Gavalas, E Pilalis, et al “Development of a prognostically relevant “angiogenic signature” in ascites from patients with advanced ovarian cancer” European Journal of Cancer, September 2013; 49(supplement 2):s716.

• Gavalas NG, Liontos M, Trachana SP, et al “Angiogenesis-related pathways in the pathogenesis of ovarian cancer.” International Journal of Molecular Sciences 2013; 14:15885-15909. doi: 10.3390/ ijms 140815885.

• Thomakos N, Trachana SP, Rodolakis A, Bamias A, Antsaklis A. “Less Radical Surgery for Fertility Preservation in Patients with Early-Stage Invasive Cervical Cancer. – Contemporary Problematics.” Gynecology & Obstetrics Journal, 2013; 3:4 http://dx.doi.org/10.4172/2161-0932.1000165.

• Karadimou A, Gavalas NG, Tsiatas M, Sereti E, Trachana SP, et al “Pre – treatment status and changes in autoantibodies, lymphocytic populations, cytokines and VEGF during Sunitinib treatment of metastatic renal cell carcinoma (Mrcc).” Translational Medicine, 2013;5:1 http://dx.doi.org/10.4172/2161-1025.1000124

• Bamias A, Sotiropoulou M, Zagouri F, Trachana P, et al. “Prognostic evaluation of tumor type and other histopathological Characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.”  European Journal of Cancer, 2012 Jul;48(10):1476-83. doi:10.1016/j.ejca.2011.09.023. Epub 2011 Oct 31.